Dianthus Therapeutics' Shares Surge as FDA Approves Changes to Lead Program

Dianthus Therapeutics (DNTH) shares surged after the FDA agreed with proposed changes to the clinical development of its lead candidate, claseprubart, a long-acting monoclonal antibody therapy. The company's stock rose as the FDA approved several modifications to the clinical trials, paving the way for further development of the drug.